DR STEPHEN LUEN: BRIDGING RESEARCH AND CLINICAL CARE IN BREAST CANCER

About Dr Stephen Luen

Dr Stephen Luen is a Medical Oncologist and translational researcher at the Peter MacCallum Cancer Centre with specialist interests in breast cancer, sarcoma, and phase 1 trials.

He is the study chair of the Breast Cancer Trials OLIO clinical trial, which aims to find out if adding the medications olaparib, or olaparib + durvalumab together, to standard chemotherapy given to pre-menopausal (18-44 year old) women with HR-positive, HER2-negative, HRD-positive breast cancer before surgery will do a better job of controlling the cancer.

Biography and Qualifications

He completed his PhD under the primary supervision of Professor Sherene Loi in 2021 investigating genomic landscapes and drivers in hormone receptor-positive, HER2-negative early breast cancers, and continues to work closely with the lab as a postdoctoral scientist.

His current research interests include the study of genomic and immune biomarkers in breast cancer, with a particular focus on investigating biological characteristics and developing clinical trials for high-risk subgroups of patients.

Additionally, he has research interests in Precision Oncology approaches, and the clinical development of novel therapeutic agents through early-phase clinical trials.

STORIES FROM OUR RESEARCHERS

Our researchers work tirelessly to develop and conduct clinical trials because they see the benefits this research brings to their patients and all those affected by breast cancer.